New endoscopic treatment methods for PPI-resistant GERD

Authors

  • Barbara Sosna School of Medicine with the Division of Dentistry in Zabrze, Department of Internal Diseases, Angiology and Physical Medicine, Center for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland
  • Dorota Bartusik-Aebisher Department of Biochemistry and General Chemistry, Medical College of The University of Rzeszów, Rzeszów, Poland https://orcid.org/0000-0002-5557-5464
  • Grzegorz Cieślar School of Medicine with the Division of Dentistry in Zabrze, Department of Internal Diseases, Angiology and Physical Medicine, Center for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland https://orcid.org/0000-0003-2210-8744
  • Aleksandra Kawczyk-Krupka School of Medicine with the Division of Dentistry in Zabrze, Department of Internal Diseases, Angiology and Physical Medicine, Center for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland https://orcid.org/0000-0003-1284-3809
  • Wojciech Latos Specialist Hospital No 2, Department of Internal Diseases, Angiology and Physical Medicine, Center for Laser Diagnostics and Therapy, Bytom, Poland

DOI:

https://doi.org/10.15584/ejcem.2021.4.6

Keywords:

diagnostics, endoscopic treatment, gastrology

Abstract

Introduction. Gastroesophageal reflux disease (GERD) is a common disease with the highest prevalence in North America. Up to 40% of patients report persistent gastroesophageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy.

Aim. The aim of this article is to complete discuss the GERD characterized by heartburn and/or regurgitation symptoms.

Material and methods. We discuss here the evidence for medical therapy for PPI nonresponsive GERD.

Analysis of the literature. GERD may present with a variety of other symptoms, including water brash, chest pain or discomfort, dysphagia, belching, epigastric pain, nausea, and bloating. In addition, patients may experience extraesophageal symptoms like cough, hoarseness, throat clearing, throat pain or burning, wheezing, and sleep disturbances.

Conclusion. There has been an increase in GERD prevalence. GERD is one of the most common gastrointestinal disorders managed by gastroenterologists and primary care physicians.

Downloads

Download data is not yet available.

References

Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101(8):1900-1920.

Frazzoni L, Frazzoni M, de Bortoli N, Tolone S, Martinucci I, Fuccio L, Savarino V, Savarino E. Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. Ann Gastroenterol. 2018;31(1):1-7.

El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871-880.

Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis, Gut. 2018;67:430-440

Yamasaki T, Hemond C, Eisa M, Ganocy S, Fass R. The Changing Epidemiology of Gastroesophageal Reflux Disease: Are Patients Getting Younger? J Neurogastroenterol Motil. 2018;24(4):559-569.

Richter JE, Rubenstein JH. Presentation and Epidemiology of Gastroesophageal Reflux Disease. Gastroenterology. 2018;154(2):267-276.

Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108(3):308-328.

Clarrett DM, Hachem C. Gastroesophageal Reflux Disease (GERD). Mo Med. 2018;115(3):214-218.

Singh M, Lee J, Gupta N, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity (Silver Spring). 2013;21(2):284-290.

Khan BA, Sodhi JS, Zargar SA, et al Effect of bed head elevation during sleep in symptomatic patients of nocturnal gastroesophageal reflux. J Gastroenterol Hepatol. 2012;27(6):1078-1082.

Sandhu DS, Fass R. Current Trends in the Management of Gastroesophageal Reflux Disease. J Chest Surg 2018;12:7-16.

Triadafilopoulos G. Stretta: a valuable endoscopic treatment modality for gastroesophageal reflux disease. World J Gastroenterol. 2014;20(24):7730-7738.

Perry KA, Banerjee A, Melvin WS. Radiofrequency energy delivery to the lower esophageal sphincter reduces esophageal acid exposure and improves GERD symptoms: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech .2012;22:283-288.

Liu HF, Zhang JG, Li J, Chen XG, Wang WA. Improvement of clinical parameters in patients with gastroesophageal reflux disease after radiofrequency energy delivery. World J Gastroenterol 2011; 17:4429-4433.

Gersin K, Fanelli R. The Stretta procedure: Review of catheter and technique evolution, efficacy and complications 2 years after introduction. Surg Endosc 2002;16(Suppl 1):PF199.

Testoni PA, Mazzoleni G, Testoni SGG. Transoral incisionless fundoplication for gastro-esophageal reflux disease: Techniques and outcomes. World J Gastrointest Pharmacol Ther. 2016;7(2):179-189.

Bazerbachi F, Krishnan K, Abu Dayyeh BK. Endoscopic GERD therapy: a primer for the transoral incisionless fundoplication procedure. Gastrointest Endosc. 2019;90(3):370-383.

Inoue H, Tanabe M, de Santiago ER, et al. Anti-reflux mucosal ablation (ARMA) as a new treatment for gastroesophageal reflux refractory to proton pump inhibitors: a pilot study. Endosc Int Open. 2020;8(2):E133-E138.

Hernández Mondragón OV, Zamarripa Mottú RA, García Contreras LF, et al. Clinical feasibility of a new antireflux ablation therapy on gastroesophageal reflux disease (with video). Gastrointest Endosc. 2020;92(6):1190-1201.

Downloads

Published

2021-12-30

How to Cite

Sosna, B., Bartusik-Aebisher, D., Cieślar, G., Kawczyk-Krupka, A., & Latos, W. (2021). New endoscopic treatment methods for PPI-resistant GERD. European Journal of Clinical and Experimental Medicine, 19(4), 322–325. https://doi.org/10.15584/ejcem.2021.4.6

Issue

Vol. 19 No. 4 (2021)

Section

REVIEW PAPERS

License

Copyright (c) 2021 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.

Most read articles by the same author(s)